Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College...
Arrowhead Pharmaceuticals presented two‑year open‑label extension data for plozasiran at the ACC 75th session, showing an 83% median triglyceride reduction in severe hypertriglyceridemia and 96% of patients dropping below the 500 mg/dL pancreatitis threshold. No adjudicated acute pancreatitis events occurred, and atherogenic lipoproteins such as remnant cholesterol and non‑HDL cholesterol improved without new safety signals. The results extend earlier Phase 2b findings and support plozasiran’s potential as a durable therapy for a broad spectrum of hypertriglyceridemia patients. Arrowhead plans to file a supplemental NDA by the end of 2026.
First Earnings Call Unveils AI‑Driven Aging Therapies
Our first ever earnings call coming up tomorrow - we are reporting our 2025 annual results. I will start the call with the 5 minute introduction to AI drug discovery and how we measure AI drug discovery productivity. In my...
Spanish Team Sustains Human Uterus Alive for 24 Hours
Scientists in Spain kept a donated human uterus alive for 24 hours using a machine that mimics the body's circulatory system, pumping modified blood through the organ.
UT San Antonio Starts Precision Rapamycin Trial for Healthy Aging
The University of Texas at San Antonio has opened a precision clinical trial to evaluate rapamycin in non‑smoking, independently living seniors. Researchers hope the study will provide hard data on dosing and safety, moving the longevity drug from hype to...
Security Gaps Exposed in Pharma AI Research Platforms Amid Rising Cyber Risks
A recent industry report warns that AI‑driven drug discovery platforms are vulnerable to cyber‑attacks and data‑privacy breaches, citing outdated hardware, fragmented compliance frameworks, and supply‑chain pressures. The findings could force pharma firms to overhaul security protocols and accelerate regulatory engagement.
GlucoTrack Shares Jump 34% as FDA IDE Submission Looms for Implantable Glucose Monitor
GlucoTrack, Inc. saw its Nasdaq‑listed shares climb 34.09% to $1.46 after reporting key milestones that set the stage for an Investigational Device Exemption (IDE) filing with the FDA in the second quarter of 2026. The company completed a first‑in‑human trial...
#AAD26: Tanabe’s Phase 3 Win for Drug Targeting Rare Diseases that Cause Pain upon Light Exposure
Tanabe Pharma announced that its oral investigational drug achieved positive results in a pivotal Phase 3 trial for erythropoietic protoporphyria (EPP) and X‑linked protoporphyria (XLP), two ultra‑rare phototoxic disorders. The study met its primary endpoint of reducing light‑induced pain episodes and...
GMO Seeds Sold to Home Gardeners
Biotech startup backed by a former Syngenta executive began selling genetically modified purple tomato seeds to home gardeners in 2024. The product, marketed as a high‑yield, disease‑resistant heirloom alternative, is the first GMO seed line directly available to consumers. Distribution...
HI-PEITHO: Catheter-Directed Therapy Bests Anticoagulation in Intermediate-Risk PE
The HI‑PEITHO trial showed that ultrasound‑facilitated, catheter‑directed fibrinolysis combined with heparin cuts the 7‑day composite risk of PE‑related death, cardiorespiratory decompensation or collapse by 61% versus anticoagulation alone. In 544 intermediate‑risk pulmonary embolism patients, the number needed to treat was...
Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension
Anumana has secured FDA 510(k) clearance for its AI‑driven pulmonary hypertension (PH) algorithm, the first software‑as‑a‑medical‑device that analyzes standard 12‑lead ECGs to flag early PH signs. The tool, built on more than 250,000 de‑identified ECGs from Mayo Clinic, demonstrated roughly...
Spatial Mapping Technique Allows Researchers to Understand Tumor Architecture
University of Illinois Urbana‑Champaign researchers unveiled GIS‑ROTA, a Geographic Information System‑augmented spatial transcriptomics framework that visualizes biological pathway activity inside tumors. Applied to estrogen‑receptor‑positive breast cancer, the method exposed distinct spatial patterns differentiating primary from metastatic lesions and highlighted regions...
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition From Oral Atypical Antipsychotics to Cobenfy™ (Xanomeline and Trospium Chloride)
Bristol Myers Squibb reported Phase 4 data showing that adults with schizophrenia can switch from oral atypical antipsychotics to Cobenfy (xanomeline‑trospium) without loss of symptom control. In an 8‑week open‑label trial, 86% of 105 patients completed the study, and mean PANSS...
GLP‑1 Drugs Could Help Prevent Cancer, Study Shows
As a medical school professor, I've watched GLP-1 drugs transform diabetes and obesity treatment. Now a Nature Cancer review reveals they may suppress cancer too. GLP-1 drugs reduce insulin resistance, lower inflammation, and cut body weight -- three of the biggest...
Weekly Biotech Roundup: Top Posts Curated by BiopharmIQ
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ - which is a comprehensive recap of the past week in BioTech. This 🧵 gathers the best BioTech posts written by some of the best & brightest 𝕏...
Leiden University Unveils Brain‑Free Microrobots That Swim, Steer and Shape‑Shift
Researchers at Leiden University introduced microrobots only a few tens of micrometres long that can swim, steer and change shape without any onboard sensors or code, moving at roughly 7 µm per second. The breakthrough relies on a nanostructured chain design...
Lantern Pharma's STAR-001 IND Clearance Triggers 10% Stock Drop
Lantern Pharma and its subsidiary Starlight Therapeutics received FDA clearance for the Investigational New Drug application of STAR-001, paving the way for a Phase 1 pediatric trial in central nervous system cancers. The announcement sent Lantern's Nasdaq‑listed shares down 10.04%...
Adjuvant Pembrolizumab Maintains Benefit-Risk Profile for High-Risk Stage II Melanoma in KEYNOTE-716 Analysis
Adjuvant pembrolizumab (Keytruda) continued to show a strong recurrence‑free survival (RFS) advantage in resected stage IIB/IIC melanoma, with median RFS not reached versus 59.2 months for placebo (hazard ratio 0.65). The 48‑month RFS rates were 68.7% with pembrolizumab compared with...
Oral GLP‑1 Battle Heats up Amid FDA Uncertainty
Oral GLP-1 wars, FDA drift, HIV franchise defense, and a few biotech landmines | Ep. 970 https://t.co/sx4kBXzgSL [ 02:30 ] oral GLP-1 battlefield heats up [ 03:08 ] convenience factor drives adoption [ 04:51 ] tolerability issues hit persistence [ 05:45 ] Novo writes $2.1...
Statin Safety and Efficacy: What Recent Studies Reveal
Recent meta‑analyses of roughly 100,000‑plus adults confirm that statins and other cholesterol‑lowering drugs cut cardiovascular events by about 30 percent relative risk, delivering an absolute 2 percent mortality benefit over four years—equivalent to one life saved for every 50 treated. The safety...
FDA Fast-Tracks Novo Nordisk’s 7.2 Mg Wegovy HD, Shaking Up Biohacking Market
The U.S. Food and Drug Administration approved Novo Nordisk’s 7.2 mg semaglutide injection, branded Wegovy HD, just 54 days after filing. The fast-track decision, the fourth under the National Priority Voucher program, expands dosing options for weight‑loss and metabolic biohackers.
Nano‑Engineered 'Living Pharmacy' Implant Delivers Three Drugs for a Month in Rats
Researchers from Northwestern, Rice and Carnegie Mellon unveiled HOBIT, a gum‑sized implant that keeps engineered cells alive and releases three biologics—an anti‑HIV antibody, a GLP‑1 peptide and leptin—for a month in animal trials. The device maintained 65% cell viability versus...
Rocket Pharma Secures FDA Approval for KRESLADI Gene Therapy, Shares Volatile
Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration granted accelerated approval for KRESLADI, its one‑time gene therapy for severe leukocyte adhesion deficiency‑I in children. The milestone triggered a swing in the company's stock, with a pre‑market surge followed...
A Woman’s Uterus Has Been Kept Alive Outside the Body for the First Time
Spanish researchers at the Carlos Simon Foundation have kept a donated human uterus alive outside the body for 24 hours using a normothermic perfusion device called “Mother” (PUPER). The machine circulates oxygenated, nutrient‑rich blood through the organ, mimicking natural circulation. This...
From Weight Loss to Longevity: Medicine Shifts Toward Prevention
It’s interesting how quickly the conversation has shifted. Not long ago, people were hesitant about weight loss injections. Now the question is whether GLP-1s should be used… for longevity. That shift alone is worth paying attention to. Because it reflects something deeper — we’re...
TTN's High Mutation Rate Reflects Size, Not Significance
TTN shows up as one of the most mutated genes in almost every cancer exome. New bioinformaticians see it and think they found something. They didn't. It's a 364-exon gene encoding the largest human protein. It collects mutations like a lint...
Why Use Living Cells? Researchers Are Making Chemicals with Enzymes Alone
Researchers at the National Laboratory of the Rockies (NLR) are advancing "cell‑free" biomanufacturing, using curated enzyme cocktails instead of living microbes to convert biomass into chemicals. By pairing high‑throughput robotics with machine‑learning analytics, they can evaluate thousands of enzyme variants...
AI‑Designed Enzymes Signal SynBio’s Sugar‑Reduction Promise
Can synbio solve sugar reduction? The @ArzedaCo + @ManeGroup partnership is a strong signal. AI-designed enzymes Cell-free manufacturing at scale Real products in market Excited to host Alexandre Zanghellini (@biopraxis) at #SynBioBeta2026. Visit the SynBioBeta website to read the full article: https://t.co/1S29MUqfWh
Β‑Hydroxybutyrate's Dual Impact on Colorectal Cancer
β-Hydroxybutyrate, a primary metabolite of ketogenic diets and its dual role in modulating colorectal cancer: from molecular mechanisms to therapeutic insights https://t.co/pPCdm2AcFo https://t.co/mPtz1Xqiep
Metformin Found to Act in Brain, Opening Low‑Cost Path to Cognitive Health
Scientists have identified a direct brain pathway—via the ventromedial hypothalamus and the Rap1 protein—through which metformin improves glucose regulation. The discovery reframes the 60‑year‑old diabetes drug as a potential low‑cost biohack for brain health and lifespan extension.
Earendil Labs Secures $787M to Accelerate AI Biologics
Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development Who is winning AI race again? https://t.co/ZW4S2zUGkS
Stanford Maps Gut‑Brain ‘Remote Control’ Linking Microbes to Memory Loss
Stanford University scientists have mapped a neural‑immune pathway by which the age‑associated bacterium Parabacteroides goldsteinii provokes gut inflammation, disrupts vagus‑nerve signaling and degrades hippocampal memory function in mice. The finding suggests dietary or microbiome‑based interventions could become a lever for...
China Shineway Pharma Posts $133 M Profit Rise Despite 17% Revenue Drop
China Shineway Pharmaceutical Group Limited announced a full‑year net profit of RMB949.95 million (about $133 million), up from RMB840.05 million a year earlier. The gain came even as revenue slipped 17% to RMB3.135 billion ($439 million), highlighting a mixed performance in China's generic drug market.
Cell and Gene Therapy Manufacturing Exposes the Cost of Delayed Digital Infrastructure
Cell and gene therapy (CGT) manufacturing is advancing quickly, yet many early‑stage firms postpone building an integrated digital backbone. The resulting manual handoffs create safety, compliance, and scalability risks. SAP’s Cell and Gene Therapy Orchestration platform introduces guided workflows, e‑signatures,...
Ocugen Inc. (OCGN): One of the Popular Penny Stocks on Robinhood
Ocugen announced completion of patient enrollment for its Phase 3 liMeliGhT trial of OCU400, a modifier gene therapy for retinitis pigmentosa. The study enrolled 140 patients in a 2:1 treatment‑to‑control ratio and will assess visual function via the LDNA mobility test....
A Precision Epigenetic Approach to Non-Invasive Lung Cancer Screening Using Gene- Specific cfDNA Methylation
A recent study demonstrates that promoter methylation of four genes—MAX, MTURN, HLA‑B and CAV1—can be detected in plasma circulating cell‑free DNA and used as a non‑invasive biomarker for lung cancer. In tumor tissue, MAX, MTURN and HLA‑B showed hypermethylation rates...
SELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026
SELLAS Life Sciences announced it will present preclinical data on its CDK9 inhibitor SLS009 (tambiciclib) at the AACR 2026 meeting in San Diego. The poster highlights the drug’s ability to induce apoptosis and lower MCL‑1 levels in acute myeloid leukemia...
Molecule‑Led Framework Prioritizes Coordination Over Technology
For years, we’ve talked about a trillion-dollar bioeconomy. The harder question has always been where to start. This new piece on the AB4S Molecule Manifesto from @LOrealGroupe, @Lallemande, @EITFood , @BASF, @Evonik, and @cradlebio offers one of the most compelling answers...
Repeated Callus Filtering Yields Red Pigment Without
Now THAT is some strong RUBY expression. Filtering transgenic callus a heap of times really pays off. Chasing the red hue without any herbicide or antibiotic pressure. Just hormones to induce callus and careful scalpel work. Some German Chammomile for...
TKI Outcomes in AML Similar Across Racial, Ethnic Groups
New real‑world analysis of 482 acute myeloid leukemia patients shows tyrosine kinase inhibitors produce comparable overall survival and event‑free survival across racial and ethnic groups. The study, using the Flatiron Health Research Database from 2015‑2023, captured patients treated with FLT3,...
Gut-Immune Link Identified in Multiple Sclerosis-Related Neuroinflammation
Researchers at Keio University discovered that intestinal epithelial cells (IECs) expressing MHC class II trigger the expansion of pathogenic Th17 cells that migrate to the spinal cord and drive neuroinflammation in multiple sclerosis (MS) mouse models. Examination of intestinal biopsies from...
Securities Lawsuits Target Corcept and Aldeyra, Sparking Investor Scrutiny
Rosen Law Firm has filed a securities‑fraud class action against Corcept Therapeutics and opened a class‑action investigation into Aldeyra Therapeutics following FDA setbacks. The actions give investors a chance to seek compensation and set a deadline of April 21, 2026...
New Therapeutic Triad Accelerates Huntington's Disease Breakthroughs
“Huntington’s Disease and The Triad of Therapeutic Conviction”. Debut blog from Eric Green, CEO of Trace Neuro, explaining why and how advances are happening in HD. Genetics, cellular understanding, and enabling modalities. https://t.co/pAr9EQs5gJ
Light‑Activated Copper Nanoparticles, Magnetic Carriers and Liposomal PDT Transform Nanomedicine
Researchers at Ruhr University Bochum, Houston Methodist and the University of Johannesburg have unveiled three nanomedicine platforms—a light‑activated copper nanoparticle, a magnetically guided superparamagnetic carrier and a liposome‑encapsulated photodynamic therapy—that each claim to dramatically improve precision for cancer or spinal‑cord...
Modern Dental Group Posts 46% Profit Jump as FDA Calendar Gains Attention
Modern Dental Group Ltd announced full‑year earnings of HK$596.97 million, a 46% increase from the prior year, with revenue climbing 11.1% to HK$3.74 billion. The results arrive as the company faces a packed FDA calendar that could unlock further market opportunities for...
R3 Bio Engineers Whole Organs, Featured in WIRED
This is so awesome. @JohnSchloendorn and Alice Gilman at R3 Bio talk through what they’re doing at R3 Bio: building something that's never existed before. They're designing genetically engineered whole organ systems. See them featured in WIRED. @WIRED full story here: https://t.co/8z5iGXR0uK
![[Comment] New Hope for Neurotrophin Targeting in Osteoarthritis Pain?](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/754aaf1faeb0d5f3b76618daddf79401.webp)
[Comment] New Hope for Neurotrophin Targeting in Osteoarthritis Pain?
Osteoarthritis (OA) remains a massive global health challenge with no disease‑modifying drugs and only modestly effective analgesics. The anti‑NGF monoclonal antibody, introduced in 2010, delivered unprecedented pain relief but was halted in 2021 after the FDA and EMA flagged joint...
![[Editorial] Politicisation of the US FDA: Eroding Integrity and Trust](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/2cbcac9eecf69b15e3915028747699be.webp)
[Editorial] Politicisation of the US FDA: Eroding Integrity and Trust
The editorial warns that increasing political interference is eroding the US Food and Drug Administration’s integrity and public trust. With a 2026 budget of $6.8 billion, the FDA remains the world’s most influential drug regulator, tasked with safeguarding safety while accelerating...
Aging Silences Brown Fat's Heat Genes via Epigenetics
Brown fat loses its heat-producing function with age due to epigenetic changes that reduce activity of key genes like PGC1A, with specific enhancers playing a critical role in maintaining this function. https://t.co/Dnnawd5r41
MiniMed Unveils MiniMed Flex, Its Smallest Insulin Pump Yet
MiniMed secured FDA clearance for the MiniMed Flex, its smallest insulin pump yet, featuring a fully smartphone‑controlled, screenless design. The pocket‑sized device is roughly half the size of the 780G and holds a 300‑unit insulin reservoir while integrating continuous glucose...
LEO Pharma Announces New Long-Term Data for SPEVIGO® (Spesolimab-Sbzo) Injection in Adults with Generalized Pustular Psoriasis at AAD 2026
LEO Pharma presented long‑term results from the five‑year EFFISAYIL ON extension, showing subcutaneous SPEVIGO® reduced generalized pustular psoriasis (GPP) flares from an average of two per year to 0.13, with 74.6% of patients experiencing no flares over three years. Intravenous SPEVIGO...